Tevogen Bio Holdings Inc
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 pat… Read more
Tevogen Bio Holdings Inc (TVGN) - Total Liabilities
Latest total liabilities as of September 2025: $12.32 Million USD
Based on the latest financial reports, Tevogen Bio Holdings Inc (TVGN) has total liabilities worth $12.32 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tevogen Bio Holdings Inc - Total Liabilities Trend (2022–2025)
This chart illustrates how Tevogen Bio Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Tevogen Bio Holdings Inc Competitors by Total Liabilities
The table below lists competitors of Tevogen Bio Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mortgage Oil Corp
PINK:MGAG
|
USA | $14.23K |
|
Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
|
USA | $1.49 Million |
|
Delixy Holdings Limited Ordinary Shares
NASDAQ:DLXY
|
USA | $22.30 Million |
|
Plus Tech Innovation PCL
BK:PTECH
|
Thailand | ฿231.97 Million |
|
Trillion Energy International Inc.
OTCQB:TRLEF
|
USA | $42.42 Million |
|
LakeShore Biopharma Co., Ltd
NASDAQ:LSB
|
USA | $867.91 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down Tevogen Bio Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tevogen Bio Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tevogen Bio Holdings Inc (2022–2025)
The table below shows the annual total liabilities of Tevogen Bio Holdings Inc from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $10.14 Million | -89.86% |
| 2024-06-30 | $99.93 Million | +139.71% |
| 2023-06-30 | $41.69 Million | +72.65% |
| 2022-06-30 | $24.15 Million | -- |